Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript

Core Insights - The company reported a negative 1% organic growth in the top line for the quarter, primarily due to larger orders in GMP proteins not repeating year-over-year, resulting in a negative $7 million impact [2] - Despite the decline in organic growth, the overall performance of the business is viewed positively, and it does not reflect the trends in the markets [2] Market Performance - In the pharmaceutical sector, the company experienced two consecutive quarters of double-digit growth, alleviating earlier concerns about potential slowdowns due to MFN rhetoric [3] - The biotech sector also continued to show positive trends, contributing to the overall market performance [3]